Y.S. Park

601 total citations
12 papers, 147 citations indexed

About

Y.S. Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Y.S. Park has authored 12 papers receiving a total of 147 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Y.S. Park's work include Colorectal Cancer Treatments and Studies (7 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Y.S. Park is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Gastric Cancer Management and Outcomes (3 papers). Y.S. Park collaborates with scholars based in South Korea, Japan and Thailand. Y.S. Park's co-authors include Ho Yeong Lim, Joon Oh Park, Sung Yong Oh, Hye Jin Choi, Ji Hyung Hong, Hyun Woo Lee, Ju-Bin Kang, Byeong Seok Sohn, S.T. Kim and Suyeon Kim and has published in prestigious journals such as Blood, Annals of Oncology and Clinical Oncology.

In The Last Decade

Y.S. Park

11 papers receiving 146 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Y.S. Park South Korea 4 113 81 70 30 19 12 147
Evgeny Gotovkin Russia 4 113 1.0× 75 0.9× 150 2.1× 35 1.2× 24 1.3× 4 200
Irene Pecora Italy 9 130 1.2× 75 0.9× 99 1.4× 20 0.7× 32 1.7× 24 207
David Alan Anthoney United Kingdom 6 126 1.1× 136 1.7× 110 1.6× 20 0.7× 17 0.9× 9 186
Tetsuji Terazawa Japan 9 96 0.8× 39 0.5× 84 1.2× 29 1.0× 22 1.2× 41 169
Thatthan Suksombooncharoen Thailand 3 135 1.2× 154 1.9× 62 0.9× 30 1.0× 16 0.8× 5 171
Juan Cundom Argentina 3 148 1.3× 150 1.9× 63 0.9× 36 1.2× 13 0.7× 6 181
Do-Youn Oh South Korea 5 159 1.4× 106 1.3× 46 0.7× 15 0.5× 30 1.6× 12 189
Ichiro Iwanaga Japan 5 128 1.1× 51 0.6× 143 2.0× 18 0.6× 13 0.7× 17 204
Jo Dent United Kingdom 5 149 1.3× 49 0.6× 76 1.1× 20 0.7× 15 0.8× 9 177
Mariaelena Casagrande Italy 8 91 0.8× 37 0.5× 45 0.6× 22 0.7× 15 0.8× 21 123

Countries citing papers authored by Y.S. Park

Since Specialization
Citations

This map shows the geographic impact of Y.S. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y.S. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y.S. Park more than expected).

Fields of papers citing papers by Y.S. Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y.S. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y.S. Park. The network helps show where Y.S. Park may publish in the future.

Co-authorship network of co-authors of Y.S. Park

This figure shows the co-authorship network connecting the top 25 collaborators of Y.S. Park. A scholar is included among the top collaborators of Y.S. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y.S. Park. Y.S. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Kim, Tae Won, Kyung-Woo Lee, Joong Bae Ahn, et al.. (2023). 618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer. Annals of Oncology. 34. S443–S443. 3 indexed citations
2.
Park, Y.S., Juhee Cho, Soo‐Yeon Kim, et al.. (2023). Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview. Blood. 142(Supplement 1). 5088–5088.
3.
Jo, Hyunji, Hong-Sik Kim, Jung Yong Hong, et al.. (2022). A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Oncology. 34(8). e323–e328. 2 indexed citations
4.
5.
Cutsem, Eric Van, Takayuki Yoshino, Heinz‐Josef Lenz, et al.. (2018). Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study. Annals of Oncology. 29(9). 1955–1963. 49 indexed citations
6.
7.
Beom, Seung‐Hoon, K.-W. Lee, Y.S. Park, et al.. (2018). A phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology. 29. viii190–viii190. 1 indexed citations
8.
Kim, T.W., Lin Shen, Jianming Xu, et al.. (2016). TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer. Annals of Oncology. 27. vi153–vi153. 6 indexed citations
9.
Yoo, Keon Hee, S.H. Park, S.T. Kim, et al.. (2015). P-104 Multi-center phase III trial of Adjuvant Chemoradiotherapy in Stomach Tumors 2 (ARTIST 2). Annals of Oncology. 26. iv29–iv29. 1 indexed citations
10.
Oh, Sung Yong, In Gyu Hwang, Jin Hee Lee, et al.. (2014). Phase Ii Trial of Epidermal Growth Factor Ointment for Patients with Erlotinib-Related Skin Effects. Annals of Oncology. 25. iv471–iv471. 1 indexed citations
11.
Park, Joon Oh, Hong-Sik Kim, Su Jin Lee, et al.. (2014). Tumour Shrinkage at 6 Weeks Predicts Favorable Clinical Outcomes in a Phase III Study of Gemcitabine and Oxaliplatin with or Without Erlotinib for Advanced Biliary Tract Cancer. Annals of Oncology. 25. iv243–iv243. 7 indexed citations
12.
Yalçın, Şuayib, Hüseyin Abalı, Nuri Faruk Aykan, et al.. (2014). Gastroenteropancreatic Neuroendocrine Tumors (Gepnet) Registry: Update from an International Collaboration. Annals of Oncology. 25. iv398–iv398. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evgeny Gotovkin Breakdown of academic impact, for papers by Irene Pecora Breakdown of academic impact, for papers by David Alan Anthoney Breakdown of academic impact, for papers by Tetsuji Terazawa Breakdown of academic impact, for papers by Thatthan Suksombooncharoen Breakdown of academic impact, for papers by Juan Cundom Breakdown of academic impact, for papers by Do-Youn Oh Breakdown of academic impact, for papers by Ichiro Iwanaga Breakdown of academic impact, for papers by Jo Dent Breakdown of academic impact, for papers by Mariaelena Casagrande
Rankless by CCL
2026